Remifentanil -propofol vs. Dexmedetromidine -propofol during fiberoptic bronchoscopy

Remifentanil ?propofol vs. Dexmedetromidine ?propofol for monitored anesthesia care during fiberoptic bronchoscopy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0000064

Enrollment

Registered

2010-12-17

Start date

2010-11-29

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : In both groups, bolus propofol (Anepol®, Hana Pharmaceutical Co., Seoul) 0.5 mg/kg was administered before infusion of the study drug. Remifentanil (PR group, 10 µg/ml, Ultiva®, Glaxo-Smith K

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 19-70 years undergoing elective flexible fiberoptic bronchoscopy ASA 1-3 class informed consent

Exclusion criteria

Exclusion criteria: baseline oxygen desaturation (resting hypoxemia, < 90%), asthma or chronic obstructive pulmonary disease or a forced expiratory volume in 1 sec (FEV1) of < 1.0 L, bradycardia (baseline heart rate [HR] < 60/min), hypotension (baseline systolic blood pressure [SBP] < 100 mmHg), in a pregnant state, those intolerant or with an allergy to the study drug those unable or who refused to give informed consent

Design outcomes

Primary

Measure	Time frame
Desaturation;Oxygen saturation trend	—

Secondary

Measure	Time frame
mean blood pressure;heart rate;arrhythmia;cough NRS (patient); satisfaction NRS (patients);cough NRS (bronchoscopist);satisfaction NRS (bronchoscopist);oral cavity suction;topical anesthesia	—

Countries

Korea, Republic of

Contacts

Public ContactJung-Hee Ryu

Seoul National University Bundang Hospital

Outcome results